Results for: Consumer Health

Sanofi SA (SNY) is nearing a deal with private equity firm Clayton Dubilier & Rice (CD&R) for the sale of a controlling stake in Opella, its consumer health division. The proposed transaction, valued at €16 billion ($17.36 billion), signifies Sanofi’s focus on innovative pharmaceuticals and vaccines, while establishing Opella as a standalone player in the consumer healthcare market. The deal, expected to close in the second quarter of 2025, has been met with mixed reactions, highlighting the strategic and financial intricacies involved.

The Food and Drug Administration (FDA) announced this week that genetic evidence of the H5N1 bird flu virus was found in pasteurized milk sold in the United States. This discovery raised concerns about the safety of milk products, prompting many consumers to wonder what this means for their health.

Pharmaceutical giant Sanofi is exploring the potential spinoff or sale of its consumer health products division, which could be valued at over $20 billion. The company has reportedly approached investment banks for proposals on the transaction, which could take place as early as the fourth quarter of this year.

Sanofi’s consumer unit boasts well-known over-the-counter products such as Zantac 360, Allegra, Nasacort, Selsun Blue, Gold Bond, and Aspercreme. The spinoff would follow a growing trend among Big Pharma companies to separate their consumer or generic drug operations as independent entities.

Several private equity firms, including Advent International, Blackstone, CVC Capital Partners, KKR, and Clayton Dubilier & Rice, have reportedly expressed interest in acquiring the unit. Sanofi plans to announce its decision on the deal’s structure, including whether to proceed with a spinoff or a sale, at a later date.